| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 25 May 2026 | 16 May 2026 |
| Choksi Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2026 inter alia to consider and approve 1.To consider and approve the standalone Audited Financial Result of the Company for the fourth Quarter and Year ended on 31st March 2026; 2. Any other item may be taken up for consideration with the permission of the Chairman and with the consent of a majority of the Directors present in the Meeting which shall include at least one independent Director. If any. | ||
| Board Meeting | 18 May 2026 | 13 May 2026 |
| Choksi Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2026 inter alia to consider and approve 1.To consider and approve the purchase of Car for the business purposes of the Company and to avail credit facilities from Bank for financing the said vehicle.; 2.To consider and approve the change of Registrar and Share Transfer Agent (RTA) of the Company; 3. Other matters as mentioned in the notice. 1. Considered and reviewed for purchasing of 1 MG Windsor car in the name of company along with loan facilities from HDFC bank. 2. Discussed and approved for initiating the process of change in Registrar and Share Transfer Agent of the Company from MUFG Intime India Private Limited to Ankit Consultancy Private Limited; 3. Considered and appoved the name of Mrs. Stela Choksi as Chief Financial Officer of the company; 4. Taken on record the resignation of Mr. Vyangesh Choksi as Chief Financial Officer of the company; 5. Other routine businesses with the permission of chair. (As Per BSE Announcement Dated on 18.05.2026) | ||
| Board Meeting | 7 Feb 2026 | 2 Feb 2026 |
| Choksi Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2026 ,inter alia, to consider and approve 1. To consider and approve the Unaudited Financial Result of the Company for the Quarter ended on 31st December 2025; 2. To Consider and approve the appointment of Mr. Ritik Pavecha (DIN: 08790431) as Additional Independent Director of the company w.e.f. 07th February, 2026; 3. To take on record the resignation of Mrs. Meenaxi Patidar (DIN: 10206356) as Independent Director of the company w.e.f. 09th January,2026; 4. Any other item may be taken up for consideration with the permission of the Chairman and with the consent of a majority of the Directors present in the Meeting, which shall include at least one independent Director. If any. 1. Considered and approved Unaudited Financial Results for the Quarter and Nine Month ended 31st December, 2025 along with the Limited review report; 2. Appointment of Mr. Ritik Pavecha (DIN: 08790431) as an Additional Director of the Company in the category of the Non-Executive Independent Director w.e.f. 07th February, 2026 subject to the Conformation of the Members 3. Taken on record the cessation of directorship of Mrs. Meenaxi Patidar (DIN: 10206356) due to resignation from the position of Non-Executive Independent Director of the company; 4. Approved postal ballot notice for seeking consent of Members of the Company for the resolutions as set out in the postal ballot Notice and other matters incidental thereto; 5. Approved the appointment of M/s. Surabhi Agrawal, Practicing Company Secretary (COP No. 23696) as Scrutinizer to scrutinize the postal ballot process in a fair and transparent manner. 6. Other routine businesses with the permission of chair. (As per BSE Announcement dated on: 07.02.2026) | ||
| Board Meeting | 14 Nov 2025 | 6 Nov 2025 |
| Choksi Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve 1. To consider and approve the Unaudited Financial Result of the Company for the Quarter and Half year ended on 30th September 2025; 2. Any other item may be taken up for consideration with the permission of the Chairman and with the consent of a majority of the Directors present in the Meeting which shall include at least one independent Director. If any. 1. Considered and approved Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2025 along with the Limited review report; 2. Other routine businesses with the permission of chair (As Per BSE Announcement Dated on: 14/11/2025) | ||
| Board Meeting | 13 Aug 2025 | 5 Aug 2025 |
| Choksi Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 inter alia to consider and approve 1. To consider and approve the Unaudited Financial Result of the Company for the Quarter ended on 30th June 2025; 2. To consider and approve the reappointment of Mr. Vyangesh Choksi (DIN: 00154926) as Whole Time Director of the company; 3. To consider the appointment of Internal Auditor of the Company for the F.Y. 2025-26; 4. To consider the appointment of Secretarial Auditor of the Company for Five Financial Year; 5. To consider the matters relating to the ensuing Annual General Meeting; 6. Any other item may be taken up for consideration with the permission of the Chairman and with the consent of a majority of the Directors present in the Meeting which shall include at least one independent Director. If an 1. Considered and approved Unaudited Standalone Financial Results for the Quarter ended 30th June, 2025 along with the Limited review report; 2. Other Agenda in the attached file. (As Per BSE Announcement Dated on: 13.08.2025) | ||
| Board Meeting | 7 Jun 2025 | 31 May 2025 |
| Choksi Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/06/2025 inter alia to consider and approve 1. To consider and approve the standalone Audited Financial Result of the Company for the fourth Quarter and Year ended on 31st March 2025; 2. 2Any other item may be taken up for consideration with the permission of the Chairman and with the consent of a majority of the Directors present in the Meeting which shall include at least one independent Director. If any. 1. Considered and approved Audited Financial Results for the Quarter and Financial Year ended 31st March, 2025 along with the along with the Auditors Report thereon, Statement of Assets and Liabilities, and Cash Flow Statement.; 2. Other routine businesses with the permission of Chair. (As Per BSE Announcement Dated on :07.06.2025) | ||
| Board Meeting | 29 May 2025 | 20 May 2025 |
| Choksi Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 inter alia to consider and approve 1. To consider and approve the standalone Audited Financial Results for the quarter and year ended 31st March 2025. 2. Any Other Business. 1. Considered and approved the Annual Secretarial Compliance Report for the year ended 31st March, 2025 as required under Regulation 24A of SEBI (LODR) 2015; 2. Other routine businesses with the permission of Chair. (As Per BSE Announcement Dated on 29.05.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
